At present, there are parallel efforts to identify biologically based high-risk subgroups benefiting from anti-angiogenic targeting, including inflammatory breast cancers28, metaplastic subtype29, and in triple negative breast cancers in BRCA1/2 mutation carriers30. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.